Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADH1B | P00325 | 1/20 | 0.45 |
| ▸ | ADH1C | P00326 | 1/20 | 0.45 |
| ▸ | ADH1A | P07327 | 1/20 | 0.45 |
| ▸ | ADH4 | P08319 | 1/20 | 0.45 |
| ▸ | ADH7 | P40394 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97095 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL7350454 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL28589060 | 0.98 | SIGMAR1 (0.48) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL7348016 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL14607493 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL10684366 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL8814716 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL2178636 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL98104 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2ADH1BADH1CADH1A | |
| SCHEMBL9669480 | 0.98 | SIGMAR1 (0.46) | SIGMAR1CYP1A2ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947378-A | Clarified polypropylene articles with improved optical properties and/or increased temperature of crystallization | BASF SE | 2013-02-27 | — | — | CN | claimed |
| WO-2023239887-A1 | NOD1 MODULATORS AND USES THEREOF | ACADEMIA SINICA (TW) | 2023-12-14 | — | — | WO | disclosed |
| CN-108602750-B | Method for producing compound having ester group | DIC株式会社 | 2022-02-11 | — | — | CN | disclosed |
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-9908848-B2 | Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-06 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-106794225-A | Leptin related peptide of myristoylation and application thereof | 奥尔巴尼医学院 | 2017-05-31 | — | — | CN | disclosed |
| WO-2005105725-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0943615-A1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | Nikken Chemicals Company, Limited (JP) | 1999-09-22 | — | — | EP | disclosed |
| EP-0279298-B1 | TRICYCLIC TRIAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4898943-A | Tricyclic triazolopyrimidine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| EP-0279298-A1 | Tricyclic triazolopyrimidine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | SIGMAR1 4240/4885CYP1A2 1873/4885ADH1B 703/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | SIGMAR1 3709/4885CYP1A2 3869/4885ADH1B 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.